For example, renal cancer patients with higher TLCD2 expression were found to have worse survival time (Atlas); upregulated SPN expression was found to associate with better survival in endometrial, breast and melanoma cancers (Atlas). This evidence concerns the gene TLCD2 and renal carcinoma.